STAT

APRIL 3, 2023

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second quarter: When is “mid-year”? Is this a second-quarter event that should be included in this scorecard, or should it be pushed to the third quarter? This is not an existential question. Now, you know, just in case.

322

322

STAT

MAY 7, 2024

Editor’s note: A livestream of the event will be embedded below at 1 p.m. It took decades for scientists to come up with treatments that could slow the progression of Alzheimer’s disease. Now patients and physicians face a new challenge: actually getting the medicines to people who might benefit from them.

266

266

STAT

SEPTEMBER 17, 2024

Called “AI in Action: Transforming Health and Human Services,” the three-hour event is hosted by the federal health department. Federal health officials wrestling with when and how to use artificial intelligence will on Wednesday host an invitation-only meeting of AI leaders across industry, academia, and government.

Medical Schools 329

Medical Schools Hospitals 329

STAT

MARCH 14, 2024

Editor’s note: A livestream of this event will be embedded below at 1 p.m. Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines?

Biosimilars 264

Biosimilars 264

STAT

APRIL 27, 2023

Editor’s Note: A livestream of the event will be embedded below at 1 p.m. Each year, STAT chooses a new class of Wunderkinds, showcasing stars of science and medicine who are in the midst of launching their careers. Read the rest…

246

246

STAT

JANUARY 13, 2023

Editor’s note: A live stream of the event will be embedded below at 1 p.m. Relive the return to an in-person J.P. Morgan Healthcare Conference with the STAT reporters who attended. Get a full rundown of the deals, data, and scuttlebutt and come away with the ideas and water-cooler chatter you need for next week. Read the rest…

246

246

STAT

APRIL 2, 2024

Here is STAT’s biotech scoreboard, our regular ledger of stock-moving biotech events, for the second quarter and middle of the year: Obesity catalysts, first. Danish drugmaker Zealand Pharma — yes, there’s another Danish drug maker in obesity — is developing a long-acting amylin analog called petrelintide.

281

281

STAT

SEPTEMBER 25, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m.   How do we ensure the population in a study best reflects the people who will get a medicine in the real world? Read the rest…

264

264

STAT

MARCH 1, 2024

CommonSpirit Health is hosting an educational event this month featuring RaDonda Vaught, the Tennessee nurse who was criminally prosecuted for accidentally killing a patient by injecting the wrong medication.

Hospitals 297

Hospitals 297

STAT

SEPTEMBER 25, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m.   How do we ensure the population in a study best reflects the people who will get a medicine in the real world? Read the rest…

259

259

STAT

JUNE 21, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Pharmacy benefit managers are intermediaries that are supposed to negotiate lower drug costs. But does the system work for patients? And how can we fix it when it doesn’t? Read the rest…

Drug Pricing 246

Drug Pricing 246

STAT

OCTOBER 2, 2024

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter: Rarely before has a large-cap biotech had so much riding on the outcome of a Phase 2 study as Amgen does with its obesity treatment MariTide , also known as AMG 133. Results are coming before the end of the year.

276

276

STAT

DECEMBER 1, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

275

275

STAT

JULY 2, 2024

H​​ere is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Late last month, Alnylam Pharmaceuticals reported positive, top-line results from its HELIOS-B clinical trial testing vutrisiran in an increasingly common heart disease called ATTR-CM.

287

287

STAT

JANUARY 13, 2025

billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will provide a boost as the industry gathers for one of its largest events of the year. Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 Intra-Cellular last month filed the drug with U.S.

Drug Development 339

Drug Development 339

STAT

MARCH 31, 2025

Maybe try it at your next networking event and report back on how it goes? A colleague at one of my old jobs used to love using the icebreaker, “Would you rather be a dog or a ghost?” ” (H/T  GQ.) Read the rest…

287

287

STAT

JULY 18, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?

Biosimilars 246

Biosimilars Drug Pricing 246

STAT

OCTOBER 2, 2023

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter: The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, (..)

287

287

STAT

JANUARY 2, 2024

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: In December, Vertex Pharmaceuticals announced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain.

Diabetes 276

Diabetes 276

STAT

MARCH 19, 2025

I had been asked to represent the American Academy of Family Physicians at this event, arriving with my relative youth and little to offer, other than an understanding of primary care practice. Twenty-five years ago this week, however, I attended the 2000 CDC Measles Elimination Meeting in Atlanta.

Vaccines 302

Vaccines Immunity Immunization 302

STAT

JUNE 9, 2023

Editor’s Note: A livestream of the event will be embedded below on Monday, June 12 at 1 p.m. ET Running a successful clinical trial is as much about execution as science, as companies and researchers must nail operational details from picking the right trial sites to ensuring patients remain in the study.

246

246

STAT

JANUARY 3, 2023

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Last year, a novel combination pill developed by Karuna Therapeutics reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial.

246

246

STAT

MARCH 19, 2025

The newsletter was supposed to be on hiatus this week, but as they say, a dark event pulled me back in.    A zombie event. STAT+ subscribers can sign up  here  to get it delivered to their inbox. Continue to STAT+ to read the full story…

245

245

STAT

MARCH 22, 2024

What happens when too many excellent, pioneering researchers enter a room? A little madness.

322

322

STAT

JANUARY 4, 2023

Continuing economic uncertainty and the threat of a recession are casting a pall over health tech in 2023 — a dramatic shift for an industry that enjoyed abundant funding in the pandemic’s early stages.

362

362

STAT

JULY 31, 2024

CHICAGO — “Buttery Biscuits & Hot Honey Gravy,” mushroom jerky, soy chicken nuggets, strawberry champagne donuts, plant-based frozen yogurt and buñuelos, white cheddar cheese puffs, chocolatey cookie dippers, egg-free Spanish cheesecake, plant-based chorizo-style empanadas … I was at the annual gathering of food (..)

361

361

STAT

MARCH 13, 2025

In a new study in the BMJ , researchers analyzed the Food and Drug Administration database where manufactures report adverse events and found that a huge number of reports come in late.   Sign up to get it  delivered in your inbox every Tuesday and Thursday.

270

270

STAT

JULY 3, 2023

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Novo Nordisk is conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health.

Hospitals 246

Hospitals 246

STAT

JANUARY 13, 2025

The health insurance giants are among 11 major companies that dropped out of the industry’s main investor event, according to the final agenda posted by J.P. STAT compared the initial schedule that J.P. Morgan circulated on Dec. 11 with the final agenda that was shared on Sunday ahead of the conference.

360

360

Pharmafile

APRIL 1, 2025

Rybelsus (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

Diabetes 59

Diabetes 59

STAT

MARCH 13, 2025

”  Housekeeping note: I’ll be in New York City next week for STAT’s  Breakthrough Summit East  event on March 20. I can’t stop saying “loraz-a-payum” thanks to Parker Posey in “The White Lotus.”  Therefore, this newsletter will take a one-week break.

310

310

STAT

OCTOBER 31, 2023

The world’s hottest summer on record is now bleeding into the fall. Instead of enjoying a cool respite from the heat, millions of Americans started September enduring temperatures so high that schools were forced to close across the country.

287

287

STAT

APRIL 4, 2023

Health tech companies are still plagued by a sluggish funding environment and a wobbling economy this quarter. Already this year, the industry has seen  the demise of once-prominent mental health startup Mindstrong , and layoffs from the likes of Color and Cerebral.

Hospitals 297

Hospitals 297

STAT

APRIL 1, 2025

If you’ll also be there, come to our STAT event on Sunday night!   Sign up  to get our biotech newsletter in your inbox. Good morning. This weekend, I’ll be at the American Academy of Neurology meeting in San Diego.

Drug Pricing 243

Drug Pricing Drug Development 243

STAT

JUNE 14, 2023

Endometriosis, a common gynecological condition, is one of health’s great mimickers. It can manifest as a variety of painful symptoms but evade detection on scans and examinations. And for the estimated 10% to 15% of women with endometriosis, it can take over a decade to get a diagnosis.

282

282

Putting Patients First Blog

MARCH 3, 2025

March 2025 Event Professionals Affinity Group Meeting Event Time: 12:00 - 1:00 p.m. Don’t miss this opportunity to connect with fellow meeting and event professionals, exchange valuable insights, and share best practices for ensuring the physical and mental well-being of all attendees.

52

52

STAT

SEPTEMBER 25, 2024

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.  Data suggested the drug might increase the risk of pain crises and “fatal events.”  billion.  

359

359